Nanopath, a Massachusetts-based molecular diagnostics company and recipient of support through multiple Massachusetts Life Sciences Center (MLSC) initiatives, has secured $25 million in Series B financing, including $2 million in non-dilutive grant funding. The financing will support manufacturing scale-up, clinical studies, and team expansion as the company advances its 15-minute point-of-care vaginitis test, designed to deliver results during a single patient visit, toward commercialization.
Nanopath’s proprietary plasmonic biosensing technology is designed to deliver laboratory-quality molecular testing without the amplification process required by traditional PCR tests. The company aims to improve access to timely, accurate diagnostics in women’s healthcare, with plans to expand its platform to additional clinical applications.
The MLSC has been a committed supporter of Nanopath’s growth since its earliest stages, providing critical funding, mentorship, and workforce development resources to help the company advance its innovative technology, attract additional investment, and scale its operations. Through the Massachusetts Next Generation (MassNextGen) Initiative, the company received more than $43,000 in funding and coaching from industry experts, helping position it to raise follow-on funding, secure grants from the National Institutes of Health and the National Science Foundation, and earn FDA Breakthrough Device Designation for its diagnostic targeting complicated urinary tract infections. Additionally, the MLSC has provided Nanopath with more than $52,000 through the Internship Challenge to support 10 interns since 2022, and a $288,000 Tax Incentive award in 2026 to support the creation of 12 new jobs.
Click here to read the full press release.
